BlossomHill Therapeutics, Inc. — Form 8-K
Filed September 18, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
BlossomHill Therapeutics, a clinical-stage biotech founded by Jean Cui, raised $168.3 million gross in an August 2026 IPO (10,516,240 shares sold). Lead candidate BH-30643 (EGFR inhibitor) received FDA Fast Track designation for C797S-positive NSCLC; Phase 1/2 SOLARA trial showed 45% objective response rate and 88% disease control rate in that population. Q2 2026 net loss was $23.8M on $21.4M R&D spend; cash position post-IPO sufficient through Q2 2028.
Why this rating
IPO funding materially extends runway for clinical programs; Fast Track designation accelerates regulatory pathway for lead asset with solid early efficacy signals in resistant NSCLC.
Price action (we called it positive)
before filing · preread $27.29 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.